Miragen | GenomeWeb


Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.

NEW YORK (GenomeWeb) – Miragen Therapeutics this week announced that its research and development collaboration with France's Servier has been extended by two years to October 2016.

Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.

This article has been updated to clarify Monsanto's relationship with Miragen and miR-168a's effect on low-density lipoprotein.

MiRagen Therapeutics has named Aimee Jackson as its director of target development and Christopher Morl as its chief business officer.

MiRagen Therapeutics this week said it has achieved the first milestone in its partnership with Les Laboratoires Servier, with the French company selecting a third target for microRNA drug development.
The move triggered an undisclosed milestone payment to MiRagen.

Miragen Therapeutics said this week that it has taken an exclusive license to intellectual property held by the University of Glasgow that is related to the use of microRNA-145 in the treatment of pulmonary arterial hypertension.
Terms of the deal were not disclosed.

Santaris Pharma and Miragen Therapeutics this week announced that they have expanded their ongoing microRNA therapeutics partnership to include six additional targets.

Though not as advanced a therapeutic technology as its RNAi cousin, microRNA received a lot of positive attention from the investment community in 2012, with the top companies in the space pulling in nearly $150 million in financing dollars over the past year.

Mirna Therapeutics this week announced that it has closed a Series C round of financing, raising $34.5 million in what is the microRNA therapeutics field's biggest single round of private investment.


In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.